[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369860-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369860-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","healthy-brca12-mutation-carriers-exhibit-a-pre-caf-signature-and-altered-epithelial-marker-expression-in-breast-tissue","Healthy BRCA1/2 mutation carriers exhibit a pre-CAF signature and altered epithelial marker expression in breast tissue","","Germline BRCA1 and BRCA2 mutations increase breast cancer risk, yet early tumorigenesis mechanisms remain insufficiently defined. This study examines preneoplastic breast tissues from healthy BRCA1 and BRCA2 mutation carriers by profiling Podoplanin (PDPN), CD10, and programmed cell death ligand 2 (PD-L2) in both epithelial and stromal compartments. Results show prevalent pre-CAF (PDPNhigh/CD10+) cells in BRCA1 stroma and also in BRCA2 carriers, with coordinated PDPN, CD10, and PD-L2 overexpression and compartment-specific PD-L2 changes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/healthy-brca12-mutation-carriers-exhibit-a-pre-caf-signature-and-altered-epithelial-marker-expression-in-breast-tissue/369860/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/healthy-brca12-mutation-carriers-exhibit-a-pre-caf-signature-and-altered-epithelial-marker-expression-in-breast-tissue/369860.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of the study in healthy BRCA1/2 mutation carriers?","Question",{"text":63,"@type":64},"To determine how BRCA1/2 mutations affect early stromal and epithelial changes by profiling expression patterns of PDPN, CD10, and PD-L2 in preneoplastic breast tissues.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does the study report about pre-CAF cells in BRCA mutation carriers?",{"text":68,"@type":64},"It finds a high prevalence of pre-CAF (PDPNhigh/CD10+) cells in the stroma of BRCA1 mutation carriers and, for the first time, also in BRCA2 mutation carriers.",{"name":70,"@type":61,"acceptedAnswer":71},"Which biomarkers were analyzed, and what changes were observed?",{"text":72,"@type":64},"PDPN, CD10, and PD-L2 were analyzed across epithelial and stromal compartments. The pre-CAFs showed overexpression of PDPN, CD10, and PD-L2, and PD-L2 expression was altered across stromal, basal, and luminal progenitor compartments with distinct localization patterns.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369860,1790211969,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nHealthy BRCA1/2 mutation carriers exhibit a pre-CAF signature and altered epithelial marker expression in breast tissue  \nFrancesco De Leonardis1,5, Maria Antonietta Di Noia1,5, Antonella Turchiano3, Stefania Martino3, Anna Maria D’Erchia1, Antonio Scilimati2, Antonella Cormio4, Angela Gurrado4, Carmen Abate2􀀍 & Nicoletta Resta3􀀍  \nGermline mutations in BRCA-1 and BRCA-2 significantly increase breast cancer risk. However, the mechanisms driving early tumorigenesis remain incompletely understood. While previous studies have primarily focused on luminal progenitors as tumor-initiating cells in BRCA-1 mut/+and BRCA-2 mut/+carriers, the impact of these mutations on the stromal microenvironment and their role in cancer initiation has notbeen thoroughly explored. We analyzed preneoplastic breast tissues from healthy BRCA-1 mut/+and BRCA-2 mut/+carriers, focusing on expression patterns and alterations of Podoplanin (PDPN), CD10, and programmed cell death ligand 2 (PD-L2) across both epithelial and stromal compartments. Our findings reveal a high prevalence of pre-CAF (PDPNhigh/CD10+ ) cells in the stroma of BRCA-1mut/+carriers and, for the first time, also in BRCA-2mut/+carriers. These pre-CAFs exhibited overexpression of PDPN, CD10, and PD-L2, supporting their role in early stromal remodeling. Additionally, we identified altered PD-L2 expression across stromal, basal, and luminal progenitor compartments, with distinct localization patterns in BRCA-1mut/+and BRCA-2mut/+ tissues. Our results suggest a potential mechanism through which BRCA1/2 mutations contribute to tumor initiation through early reprogramming of both stromal and epithelial compartments. These findings highlight the pivotal role of the stromal microenvironment in BRCA1/2-associated breast cancer initiation and underscore the importance of simultaneously investigating epithelial and stromal alterations in cancer risk assessment.  \nKeywords BRCA1, BRCA2, Podoplanin (PDPN), Programmed cell death ligand 2 (PD-L2), CAFs, CD10  \nAbbreviations  \nMEP Myoepithelial cells  \nCAFs Cancer associated fibroblasts  \nL. prog Luminal progenitor  \nFMO Fluorescence minus one  \nBRCA Breast cancer-associated tumor suppressor genes  \nBreast cancer (BC) is a highly heterogeneous disease, including a wide group of immunophenotypically, genetically, and epigenetically distinct subtypes1,2. Germline mutations in BRCA-1 and BRCA-2 significantly increase the lifetime risk of BC, with estimates reaching up to 80%, compared to the general population3. BRCA mutations are not uniform in their effects. Indeed, different mutations within the BRCA-1 and BRCA-2 genes are associated with varying levels of breast cancer risk. Some mutations confer a higher risk of early-onset breast cancer, while others are associated with lower penetrance4.  \n1Department of Bioscience, Biotechnologies and Environment, University of Bari “Aldo Moro”, 70125 Bari, Italy.  \n2Department of Pharmacy-Pharmaceutical Sciences, University of Bari “Aldo Moro”, Via E. Orabona 4, 70125 Bari, Italy. 3Medical Genetics Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70125 Bari, Italy. 4Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70125 Bari, Italy. 5Francesco De Leonardis and Maria Antonietta Di Noia contributed equally to this work. 􀀍 email: [carmen.abate@uniba.it](carmen.abate@uniba.it); [nicoletta.resta@uniba.it](nicoletta.resta@uniba.it)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nThe mammary gland is composed of epithelial and stromal compartments, where luminal and basal (myoepithelial) cells form the functional epithelium, and fibroblasts dominate the stroma. Stromal fibroblasts play a critical role in maintaining tissue homeostasis by secreting extracellular matrix (ECM) components and ","cbCaiiHddVCjiGpn","https://ap.wps.com/l/cbCaiiHddVCjiGpn","pdf",5612982,11,"English","# Abstract\n## Key findings and rationale\n## Biomarker profiling in epithelial and stromal compartments\n## Implications for early tumor initiation","[{\"question\":\"What was the main aim of the study in healthy BRCA1/2 mutation carriers?\",\"answer\":\"To determine how BRCA1/2 mutations affect early stromal and epithelial changes by profiling expression patterns of PDPN, CD10, and PD-L2 in preneoplastic breast tissues.\"},{\"question\":\"What does the study report about pre-CAF cells in BRCA mutation carriers?\",\"answer\":\"It finds a high prevalence of pre-CAF (PDPNhigh/CD10+) cells in the stroma of BRCA1 mutation carriers and, for the first time, also in BRCA2 mutation carriers.\"},{\"question\":\"Which biomarkers were analyzed, and what changes were observed?\",\"answer\":\"PDPN, CD10, and PD-L2 were analyzed across epithelial and stromal compartments. The pre-CAFs showed overexpression of PDPN, CD10, and PD-L2, and PD-L2 expression was altered across stromal, basal, and luminal progenitor compartments with distinct localization patterns.\"}]","Healthy BRCA1/2 mutation carriers exhibit a pre-CAF signature and altered epithelial marker expression in breast tissue | PDF",1790184925,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7334e6b402707a96a1c9d680592d6d9.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ad45d3e278a1deb22e55fc20ce424e8.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c4634a0ee81881a8d59d69d1aa34eae.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/849ea3b504e112314b2e1357ab03f282.webp",980,1287]